Bristol-myers Squibb & Astrazeneca


PARIS and LONDON, November 29, 2011 - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE/LSE: AZN) announced today that the European Commission has granted marketing authorisation for KOMBOGLYZETM (saxagliptin and metformin HCl immediate-release fixed dose combination) that will cover the 27 Member States of the European Union.
Older News
S M T W T F S
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 1 2 3
Copyright© 2011 The Gaea Times